Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL-Reference-Cited by-同舟云学术

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

Published:2020-11-11 Issue:5 Volume:17 Page:1288-1293
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Bhuyan Prakash K.¹^ORCID,Dallas Michael¹,Kraynyak Kim¹,Herring Timothy¹^ORCID,Morrow Matthew¹,Boyer Jean¹,Duff Susan¹,Kim Joseph¹,Weiner David B.²

Affiliation:

1. Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USA

2. Wistar Institute, Philadelphia, PA, USA

Funder

Inovio Pharmaceuticals

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1823778

Reference17 articles.

1. Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in the world. Summary Report 17 June 2019. 2019.

2. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

3. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies;Molecular Therapy;2024-07

2. Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies;Life Science Alliance;2024-03-21

3. Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?;Tumour Virus Research;2023-12

4. Vaccines for HPV-associated diseases;Molecular Aspects of Medicine;2023-12

5. LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition;Frontiers in Immunology;2023-08-30